** Shares of U.S. drugmaker Eli Lilly LLY.N rise 1.70% to $840.08 premarket
** Peer Novo Nordisk NOVOb.CO posted Q4 operating profit above expectations
** Sales of its blockbuster weight-loss drug Wegovy more than doubled
** Novo lost out to Lilly in the fourth quarter in terms of total weekly prescriptions written for Wegovy compared to Lilly's Zepbound in the United States, the biggest market
** Last month, LLY forecast Q4 sales of Zepbound below Wall Street estimates
** LLY reports its quarterly results on Thursday
** LLY shares gained ~32% in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.